[ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026", "title": "Kvartalsrapport Q1 2026", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a640a22fadfde25cdc5f072a65785de3a", "date": "2026-05-13", "period": "2026-q1", "form_type": "interim-report", "report_key": "2026:q1", "filename": "Interim_Report_Q1_2026_Oncopeptides_AB.pdf", "text_chars": 20704, "sha256": "26bd05e351472334f0496a128c4ae5d62c86cb43231271c4e277ef9da186d84b", "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html", "chars": 20704 } ] }, { "doc_id": "nasdaq-nordic-arsredovisning-2025", "title": "Årsredovisning 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ad8459a263a0e8ceb0fe0e33b3425b0e7", "date": "2026-04-28", "period": "2025-annual", "form_type": "annual-report", "report_key": "2025:annual", "filename": "Arsredovisning_2025_260428_Se.pdf", "text_chars": 246195, "sha256": "20d4aa61cf83a6cd35f30949b5834bde2b21e8347a3c91a4002177ce23079bba", "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025", "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025/part-001.html", "chars": 179971 }, { "number": 2, "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025/part-002.html", "chars": 66222 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025", "title": "Kvartalsrapport Q4 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a009c174c018035acc6195b9c762a26a9", "date": "2026-02-19", "period": "2025-q4", "form_type": "year-end-report", "report_key": "2025:q4", "filename": "Bokslutskommunike_2025.pdf", "text_chars": 21313, "sha256": "320e8f30e1760f76f8ac269eadfcaa43bbe21db53b07296d0db8c2c81c8c7992", "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html", "chars": 21313 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025", "title": "Kvartalsrapport Q3 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ac855f4271b5a776cd2a4f4c5c172f305", "date": "2025-11-05", "period": "2025-q3", "form_type": "interim-report", "report_key": "2025:q3", "filename": "Q3_Report_2025_Oncopeptides_AB.pdf", "text_chars": 23475, "sha256": "9491cff09c4ba348f5b343f6d21419ffa79d2a2fd1d32733ad72b7a6f0dd7505", "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html", "chars": 23475 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025", "title": "Kvartalsrapport Q2 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a10493486bbc8a9087ef3c90e5cb50d5a", "date": "2025-08-21", "period": "2025-q2", "form_type": "interim-report", "report_key": "2025:q2", "filename": "Q2_Rapport_2025_Oncopeptides_AB.pdf", "text_chars": 20247, "sha256": "7651de6672d75b6d9d2938f6b81f2a272aa5b1116fbde1293e9e67f97de59237", "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html", "chars": 20247 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025", "title": "Kvartalsrapport Q1 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ab8595f10b25ed5bbcdb9f37eff2bbeb3", "date": "2025-05-15", "period": "2025-q1", "form_type": "interim-report", "report_key": "2025:q1", "filename": "Interim_Report_Q1_2025_Oncopeptides_AB.pdf", "text_chars": 20831, "sha256": "104d2a975270a2f51b1a1dbd9c25fefccc292e66d0bdf0d80ae2ce31b8efb89c", "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html", "chars": 20831 } ] }, { "doc_id": "nasdaq-nordic-arsredovisning-2024", "title": "Årsredovisning 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/afb04baf8ae0ac2231f36921bc3d4d8d9", "date": "2025-04-28", "period": "2024-annual", "form_type": "annual-report", "report_key": "2024:annual", "filename": "Arsredovisning_2024_Oncopeptides_AB.pdf", "text_chars": 269301, "sha256": "1640dd577580d93bfbd18edbb969556c84b6c456ee499e51a6fcd60cadee3406", "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024", "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024/part-001.html", "chars": 178236 }, { "number": 2, "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024/part-002.html", "chars": 91063 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024", "title": "Kvartalsrapport Q4 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a620844aaae3c8c829e35bd0c666d17f6", "date": "2025-02-27", "period": "2024-q4", "form_type": "year-end-report", "report_key": "2024:q4", "filename": "Bokslutskommunike_2024_Oncopeptides_AB.pdf", "text_chars": 26255, "sha256": "24cdb5a54e134e6bd455a87673cd68ea9b8088aaf89f0647c11f697be74c25a8", "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2024", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2024", "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html", "chars": 26255 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024", "title": "Kvartalsrapport Q3 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a7cdc25bf84d076ff5cb18e3dcf190981", "date": "2024-11-07", "period": "2024-q3", "form_type": "interim-report", "report_key": "2024:q3", "filename": "Q3_Report_2024_Oncopeptides_AB.pdf", "text_chars": 34486, "sha256": "6d8f6d32ed2185c96f327cdb7e3c9abe54ef63a699b1de5730cffea9a446c0ba", "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html", "chars": 34486 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024", "title": "Kvartalsrapport Q2 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a952a4b468952249f0f72429e317671b9", "date": "2024-08-14", "period": "2024-q2", "form_type": "interim-report", "report_key": "2024:q2", "filename": "Q2_Rapport_2024_Oncopeptides_AB_publ.pdf", "text_chars": 31881, "sha256": "2fb9c2eb83d318f884550d60c72ca62540133b468c579722b628dc4d85b0bab4", "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html", "chars": 31881 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024", "title": "Kvartalsrapport Q1 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ac36b75da49df57fed7da5dd44741856a", "date": "2024-05-30", "period": "2024-q1", "form_type": "interim-report", "report_key": "2024:q1", "filename": "INTERIM_REPORT_for_Q1_2024_-_Oncopeptides_AB.pdf", "text_chars": 33589, "sha256": "92d5dee1d7fd343fd21517f2f7513483139fba845498473e45ec278dd73160b2", "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2024", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2024", "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html", "chars": 33589 } ] }, { "doc_id": "nasdaq-nordic-arsredovisning-2023", "title": "Årsredovisning 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/af6ea68f7a471b0d2bdac0312f245a792", "date": "2024-04-22", "period": "2023-annual", "form_type": "annual-report", "report_key": "2023:annual", "filename": "Oncopeptides_AB_publ_Arsredovisning_2023.pdf", "text_chars": 278369, "sha256": "5927414fddccc6e74bc7495c6be785d134a1885afed9e0eb8c686471e72067f9", "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023", "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023/part-001.html", "chars": 177330 }, { "number": 2, "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023/part-002.html", "chars": 101037 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023", "title": "Kvartalsrapport Q4 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a5b34b74e64e0c5e0352da16de120def7", "date": "2024-02-27", "period": "2023-q4", "form_type": "year-end-report", "report_key": "2023:q4", "filename": "Q4_Bokslutskommunike_2023_20240227.pdf", "text_chars": 35422, "sha256": "cca77af0ef2c322e6604b48150f366fbfdaea1545b80e6c4b350263685d1f394", "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2023", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2023", "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html", "chars": 35422 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023", "title": "Kvartalsrapport Q3 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a1cfef8bffada0217bc4e842b5745e094", "date": "2023-11-08", "period": "2023-q3", "form_type": "interim-report", "report_key": "2023:q3", "filename": "Interim_Report_Q3_2023.pdf", "text_chars": 38994, "sha256": "0685206209f958daff1ce1a50b99bfbe38ccf9c3f2a6d3652f6f0dce6be8f5f9", "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html", "chars": 38994 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023", "title": "Kvartalsrapport Q2 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a33a1b06248aa2692803318f12b2e541e", "date": "2023-08-10", "period": "2023-q2", "form_type": "interim-report", "report_key": "2023:q2", "filename": "Oncopeptides_AB_Delarsrapport_Q2_2023.pdf", "text_chars": 33250, "sha256": "511489b44ac646f8143b032624333f57f51857336a5eb25edf04a985afc0f883", "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html", "chars": 33250 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023", "title": "Kvartalsrapport Q1 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a485b398b49174d0cba5f2f87aa103a27", "date": "2023-05-04", "period": "2023-q1", "form_type": "interim-report", "report_key": "2023:q1", "filename": "Interim_Report_Q1_2023_ENG_Oncopeptides.pdf", "text_chars": 29709, "sha256": "e936c0643f451fbbc6ac9a1b48b71c0c4bcdf1f3b5eb2dde58ef2229954b2e00", "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html", "chars": 29709 } ] }, { "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata", "title": "MFN bolagssida och bolagsmetadata", "source": "MFN", "source_class": "mfn", "source_url": "https://mfn.se/all/a/oncopeptides", "date": null, "period": null, "form_type": "company-page", "report_key": null, "filename": "company.txt", "text_chars": 12619, "sha256": "36c0518a8d2210243547048c29d6148c63aed257c49c09bd1f3ee5ddac03bde7", "url": "/company/oncopeptides/documents/mfn-mfn-bolagssida-och-bolagsmetadata", "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/mfn-mfn-bolagssida-och-bolagsmetadata", "txt_url": "/company/oncopeptides/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt", "parts": [ { "number": 1, "url": "/company/oncopeptides/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html", "chars": 12619 } ] } ]